| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Lim JK | |
| Ooka K | |||
| P2860 | cites work | A diverse range of gene products are effectors of the type I interferon antiviral response | Q24626018 |
| Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 | Q26768128 | ||
| Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review | Q26829390 | ||
| Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection | Q27485119 | ||
| Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study | Q27490163 | ||
| Hepatitis C virus infection | Q27861002 | ||
| Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis | Q28076352 | ||
| Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons | Q28274676 | ||
| Disappearance of serum HCV-RNA after short-term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis-like serological manifestations | Q28373798 | ||
| Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 | ||
| Analysis of a successful immune response against hepatitis C virus | Q29619507 | ||
| Mechanism of action of interferon and ribavirin in treatment of hepatitis C | Q29619805 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help | Q29620766 | ||
| Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia | Q30304065 | ||
| Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein | Q30421625 | ||
| Systemic vasculitis in patients with hepatitis C. | Q31984528 | ||
| Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial | Q32015815 | ||
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Pathologist's puzzle: Membranoproliferative glomerulonephritis-like features in cryoglobulinemic glomerulonephritis | Q33353123 | ||
| Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results | Q33383222 | ||
| Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine | Q72268692 | ||
| Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C | Q72281870 | ||
| Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia | Q73911049 | ||
| Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations | Q74400800 | ||
| A case of progression from type II cryoglobulinaemia to Waldenstrom's macroglobulinaemia in a patient with chronic hepatitis C | Q81803655 | ||
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis | Q94502258 | ||
| Hepatitis C treatment concomitant to chemotherapy as "salvage" therapy in children with hematologic malignancies | Q43233398 | ||
| Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. | Q43296395 | ||
| Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin | Q43705180 | ||
| Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection | Q43717040 | ||
| Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome | Q43788277 | ||
| Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients | Q43874759 | ||
| Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy | Q44285998 | ||
| A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients | Q44365626 | ||
| Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting | Q44480405 | ||
| Hepatitis C virus infection with and without cryoglobulinemia as a case of Churg-Strauss syndrome | Q44906425 | ||
| The effect of combination therapy with interferon and cryofiltration on mesangial proliferative glomerulonephritis originating from mixed cryoglobulinemia in chronic hepatitis C virus infection. | Q44952494 | ||
| Chronic hepatitis C virus hepatitis and psoriasis: no longer a contraindication to interferon use in the era of biological agents? | Q45354087 | ||
| Induction of clinical remission with adalimumab-methotrexate combination therapy in a patient with rheumatoid arthritis and concomitant hepatitis C virus infection | Q45366264 | ||
| Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. | Q45377393 | ||
| Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. | Q45410555 | ||
| Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. | Q45766394 | ||
| Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus | Q45772528 | ||
| Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. | Q46367575 | ||
| Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. | Q46461224 | ||
| Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy | Q47841043 | ||
| Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma | Q47909633 | ||
| Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. | Q50556918 | ||
| Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. | Q50559814 | ||
| Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. | Q50570866 | ||
| A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. | Q50573914 | ||
| Late autoimmune hepatitis after hepatitis C therapy. | Q51031382 | ||
| Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. | Q54052083 | ||
| Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases | Q71429316 | ||
| Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C | Q71828922 | ||
| Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C | Q72229762 | ||
| Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 | Q33407192 | ||
| Hepatitis C virus-related heat-insoluble cryoglobulinemia and thrombotic microangiopathy | Q33408235 | ||
| Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner | Q33822643 | ||
| Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature | Q33867221 | ||
| A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome | Q33916375 | ||
| Immunopathogenesis of hepatitis C virus in the immunosuppressed host | Q34148593 | ||
| Azathioprine: old drug, new actions | Q34190823 | ||
| Therapy for hepatitis C virus-related cryoglobulinemic vasculitis | Q34370279 | ||
| Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. | Q34719466 | ||
| Impact of immunosuppressive therapy on recurrence of hepatitis C. | Q34936148 | ||
| Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis | Q35894975 | ||
| PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. | Q36089136 | ||
| Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment | Q36334736 | ||
| Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis | Q36368134 | ||
| Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents | Q36479541 | ||
| Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis | Q36530402 | ||
| Flying under the radar: the immunobiology of hepatitis C. | Q36635544 | ||
| Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis | Q37087258 | ||
| Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature | Q37132458 | ||
| Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence | Q37349067 | ||
| Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease | Q37355530 | ||
| Off-label use of rituximab in a tertiary Queensland hospital | Q37491312 | ||
| Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer | Q37722447 | ||
| The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights | Q37732574 | ||
| Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients | Q37838047 | ||
| Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review | Q37892162 | ||
| Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies | Q38194499 | ||
| Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature. | Q38196327 | ||
| Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial | Q38415846 | ||
| Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. | Q38530211 | ||
| Diagnosis and Management of Hepatitis C. | Q38541405 | ||
| Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy | Q38703524 | ||
| Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection | Q39007700 | ||
| Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic | Q39775580 | ||
| Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation | Q39911623 | ||
| KDIGO clinical practice guideline for the care of kidney transplant recipients | Q39936865 | ||
| Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. | Q40297644 | ||
| Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritis | Q40622354 | ||
| Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation | Q40765042 | ||
| Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial | Q40780423 | ||
| Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list | Q40836347 | ||
| Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. | Q40981955 | ||
| Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease | Q41222268 | ||
| Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. | Q41547422 | ||
| An interferon-free antiviral regimen for HCV after liver transplantation | Q41668021 | ||
| Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients | Q41670443 | ||
| Classic polyarteritis nodosa associated with hepatitis C virus infection: a case report | Q41867680 | ||
| Outcome of combination antiviral therapy in chronic hepatitis C virus infection during therapy of acute lymphoblastic leukemia | Q42080206 | ||
| Concomitant therapy of Crohn's disease and hepatitis C with budesonide and antivirals | Q42127737 | ||
| Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy | Q42162220 | ||
| Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series. | Q42210289 | ||
| Treatment of acute hepatitis C in breast cancer patient: a case report | Q42232094 | ||
| All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection | Q42238837 | ||
| Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial | Q42242013 | ||
| Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia | Q42243876 | ||
| Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report | Q42256943 | ||
| Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients | Q42274394 | ||
| Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial | Q42733618 | ||
| Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. | Q42983064 | ||
| Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. | Q42984479 | ||
| Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. | Q42985072 | ||
| Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials | Q42990077 | ||
| Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study | Q42991500 | ||
| 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. | Q42992965 | ||
| Effects of corticosteroids on HCV infection | Q42994324 | ||
| Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. | Q42997068 | ||
| Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. | Q42997987 | ||
| Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus | Q42999050 | ||
| Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. | Q42999434 | ||
| Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. | Q43001526 | ||
| Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha | Q43037270 | ||
| Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. | Q43041133 | ||
| Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. | Q43042223 | ||
| Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept | Q43047008 | ||
| Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment | Q43048652 | ||
| Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. | Q43049480 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 206-227 | |
| P577 | publication date | 2016-09-28 | |
| P1433 | published in | Journal of clinical and translational hepatology | Q27726496 |
| P1476 | title | Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy | |
| P478 | volume | 4 |
Search more.